Oral Antidiabetic Agents in Pregnancy and Lactation: A Paradigm Shift?
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Objective: To provide information on the use of oral antidiabetic agents in pregnancy and breast-feeding. Data Sources: Primary articles were identified by a MEDLINE search (1966–March 2007) using the MeSH headings: pregnancy in diabetics, pregnancy, polycystic ovary syndrome, hypoglycemic agents, glipizide, glyburide, metformin, rosiglitazone, pioglitazone, clinical trial, controlled clinical trial, multicenter study, randomized controlled trial, case–control studies, and cohort studies. Study Selection and Data Extraction: All studies using oral antidiabetic agents in pregnancy were evaluated and relevant data were included in the discussion. Data Synthesis: Studies of glyburide and glipizide have found little or no transfer of these drugs across the placenta, whereas metformin and rosiglitazone cross readily. Animal studies have found no evidence to suggest that glyburide, glipizide, metformin, or rosiglitazone are teratogenic. In gestational diabetes, glyburide was safe and efficacious; however, 16–19% of women failed to achieve optimal glucose control. No developmental toxicity in infants was observed when metformin was used before and throughout pregnancy in women with polycystic ovarian syndrome (PCOS). Some of the studies involving patients with type 2 diabetes had methodological problems. A randomized controlled trial using metformin for gestational diabetes in the third trimester is underway. The human information is inadequate to evaluate the risk of glipizide or the thiazolidinediones in pregnancy. In breast milk, 3 studies measured nonsignificant amounts of metformin and one study was unable to detect either glyburide or glipizide. Conclusions: Neither glyburide nor metformin has caused developmental toxicity in humans. Glyburide has been used for the treatment of gestational diabetes, and metformin has been used in women with PCOS who eventually became pregnant. Additional trials are needed to better define the benefits and risks of oral antidiabetic agents in pregnancy. Metformin, glyburide, and glipizide appear to be compatible with breast-feeding.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A comparison of glyburide and insulin in women with gestational diabetes mellitus
Langer, O., Conway, D. L., Berkus, M. D., Xenakis, E. M.-J., & Gonzales, O. (2000) · New England Journal of Medicine · doi:10.1056/nejm200010193431601 · Cited by 924
American Diabetes Association (2004) · Diabetes Care · doi:10.2337/diacare.27.2007.s88 · Cited by 916
Placental passage of metformin in women with polycystic ovary syndrome
Vanky, E., Zahlsen, K., Spigset, O., & Carlsen, S. M. (2005) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.11.051 · Cited by 245
Jacobson, G. F., Ramos, G. A., Ching, J. Y., Kirby, R. S., Ferrara, A., & Field, D. R. (2005) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2005.03.018 · Cited by 177
Glyburide for the treatment of gestational diabetes
Kremer, C. J., & Duff, P. (2004) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.02.032 · Cited by 126
Chmait, R., Dinise, T., & Moore, T. (2004) · Journal of Perinatology · doi:10.1038/sj.jp.7211147 · Cited by 118
Metformin, pre-eclampsia, and pregnancy outcomes in women with polycystic ovary syndrome
Glueck, C. J., Bornovali, S., Pranikoff, J., Goldenberg, N., Dharashivkar, S., & Wang, P. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01251.x · Cited by 115
Use of glyburide for the treatment of gestational diabetes: the San Antonio experience
Conway, D. L., Gonzales, O., & Skiver, D. (2004) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767050310001650725 · Cited by 112
Predictors of glyburide failure in the treatment of gestational diabetes
Kahn, B. F., Davies, J. K., Lynch, A. M., Reynolds, R. M., & Barbour, L. A. (2006) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000218704.28313.36 · Cited by 85
Transfer of glyburide and glipizide into breast milk
Feig, D. S., Briggs, G. G., Kraemer, J. M., Ambrose, P. J., Moskovitz, D. N., Nageotte, M., Donat, D. J., Padilla, G., Wan, S., Klein, J., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.8.1851 · Cited by 81
Self-citation
Cited by
Kung, J., & Henry, R. R. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.691963 · Cited by 198
“In animal studies, pioglitazone showed increased post-implantation fetal losses at doses 10 -- 40 times the maximum recommended human dose [77].”
BackgroundButalia, S., Gutierrez, L., Lodha, A., Aitken, E., Zakariasen, A., & Donovan, L. (2017) · Diabetic Medicine · doi:10.1111/dme.13150 · Cited by 170
Dhulkotia, J. S., Ola, B., Fraser, R., & Farrell, T. (2010) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2010.06.044 · Cited by 145
The use of glyburide in the management of gestational diabetes mellitus: A meta-analysis
Zeng, Y.-C., Li, M.-J., Chen, Y., Jiang, L., Wang, S.-M., Mo, X.-L., & Li, B.-Y. (2014) · Advances in Medical Sciences · doi:10.1016/j.advms.2014.03.001 · Cited by 76
Lee, H., Wei, D., & Loeken, M. R. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2451 · Cited by 39
Metadata
- Authors
- Feig, D. S., Briggs, G. G., & Koren, G.
- Venue
- Annals of Pharmacotherapy
- Publisher
- SAGE Publications
- Published
- 2007-07
- Volume
- 41
- Issue
- 7-8
- Pages
- 1174-1180
- ISSN
- 0012-6578 (ISSN-L)
- 1060-0280
- 1542-6270
- OpenAlex
- W2106024233
- Cited by
- 73
- References
- 11
- FWCI
- 10.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oral Antidiabetic Agents in Pregnancy and Lactation: A Paradigm Shift? https://app.cochat.ai/papers/10.1345/aph.1k045
- The paper
- Feig, D. S., Briggs, G. G., & Koren, G. (2007). Oral Antidiabetic Agents in Pregnancy and Lactation: A Paradigm Shift? Annals of Pharmacotherapy. https://doi.org/10.1345/aph.1k045
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.